To market PanTheryx’s proprietary nutritional intervention for paediatric infectious diarrhoea
PanTheryx, a global medical nutrition company based in Boulder, Colorado and Dr Reddy’s Laboratories (DRL) announced a multi-country supply and licensing agreement. The agreement grants DRL the exclusive right to market and distribute PanTheryx’s breakthrough nutritional intervention, DiaResQ, for infectious diarrhoea in India and Nepal and in process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets. DRL will market the product in India and Nepal under the ‘Reliqua’ brand. DiaResQ helps to promote intestinal repair and boost natural immune defences, resulting in the restoration of normal digestive function.
Mark A Braman, President and Chief Executive Officer, PanTheryx, “The opportunity to work with DRL to broadly introduce DiaResQ represents a significant milestone for our company. This agreement covers some of the largest and most promising markets throughout the world for PanTheryx and its products. This partnership further validates DiaResQ’s potential to improve the well-being and quality of life of millions of children and their families globally.”
GV Prasad, Co-chairman and Chief Executive Officer, DRL stated “By adding Reliqua to our existing portfolio of gastrointestinal brands, DRL can provide an important new tool for healthcare practitioners across the many markets we serve. Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it.”
Comments are closed.